A panel discussion covers considerations within REMS programs aimed at minimizing risks associated with bispecific therapy.
NOTE: Not all FDA-approved bispecific antibodies are associated with a REMS protocol.
Medtronic receives FDA approval for Percept RC neurostimulator with exclusive BrainSense technology, expanding treatment options for movement disorders.;
AstraZeneca and Ionis have received FDA approval for Waiuna, their treatment for polyneuropathy in life-threatening disease transthyretin-mediated amyloidosis (ATTR).